世界の日光角化症治療市場2022-2030:治療別(局所、手術、光線力学療法)、薬剤分類別、最終用途別、地域別

【英語タイトル】Actinic Keratosis Treatment Market Size, Share & Trends Analysis Report By Therapy (Topical, Surgery, Photodynamic Therapy), By Drug Class, By End-use, By Region, And Segment Forecasts, 2022 - 2030

Grand View Researchが出版した調査資料(GRV22NV006)・商品コード:GRV22NV006
・発行会社(調査会社):Grand View Research
・発行日:2022年10月28日
・ページ数:170
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥880,600見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥1,028,600見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥1,324,600見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Grand View Research社は、世界の日光角化症治療市場規模が、2022年から2030年の間に年平均4.1%成長し、2030年までに89.3億ドルに達すると予測しています。当調査レポートでは、日光角化症治療の世界市場について総合的に調査・分析を行い、調査手法・範囲、エグゼクティブサマリー、産業見通し、治療別(局所療法、手術、光線力学療法)分析、薬剤分類別(ヌクレオシド代謝阻害剤、NSAID、免疫応答調整剤、光増強剤)分析、最終用途別(病院、クリニック、在宅医療、その他)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、競争分析、企業情報などの構成でまとめています。なお、当書に掲載されている企業情報には、ALMIRALL S.A.、LEO PHARMA A/S、SUN PHARMACEUTICAL INDUSTRIES LTD.、NOVARTIS AG、GALDERMA、ORTHO DERMATOLOGICS (BAUSCH HEALTH COMPANIES INC.)、BIOFRONTERA AG、HILL PHARMACEUTICALS, INC.などが含まれています。
・調査手法・範囲
・エグゼクティブサマリー
・産業見通し
・世界の日光角化症治療市場規模:治療別
- 局所療法の市場規模
- 手術の市場規模
- 光線力学療法の市場規模
・世界の日光角化症治療市場規模:薬剤分類別
- ヌクレオシド代謝阻害剤の市場規模
- NSAIDの市場規模
- 免疫応答調整剤の市場規模
- 光増強剤の市場規模
・世界の日光角化症治療市場規模:最終用途別
- 病院における市場規模
- クリニックにおける市場規模
- 在宅医療における市場規模
- その他最終用途における市場規模
・世界の日光角化症治療市場規模:地域別
- 北米の日光角化症治療市場規模
- ヨーロッパの日光角化症治療市場規模
- アジア太平洋の日光角化症治療市場規模
- 中南米の日光角化症治療市場規模
- 中東・アフリカの日光角化症治療市場規模
・競争分析

Actinic Keratosis Treatment Market Growth & Trends

The global actinic keratosis treatment market size is anticipated to reach USD 8.93 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 4.1% from 2022 to 2030. The market is expected to witness growth opportunities owing to factors such as the wide availability of actinic keratosis therapeutics, rising awareness about the disease, and the rise in AK treatment. Moreover, the increasing prevalence of actinic keratosis and the rising geriatric population across the globe are expected to fuel the market growth during the forecast period.

Invasive squamous cell carcinoma may develop from AK when it becomes malignant (iSCC). Despite the fact that there are a number of potential causes for iSCC, AK is one of the most frequent ones. Additionally, basal cell carcinoma and non-melanoma skin cancer could result from AK. As a result, the demand for AK products across sales channels is being driven by the early diagnosis and treatment of actinic keratosis as a preventive strategy for comorbidities.

In addition, future pipeline medications and the increased use of combination therapy are key market drivers. For instance, Almirall, S.A. has Klisyri (extended label) in phase III of R&D. Furthermore, a rise in the acceptance and commercialization of innovative drugs is another factor that is predicted to fuel market growth. Moreover, increased R&D activities are expected to accelerate the approval of novel drugs used in the treatment of actinic keratosis, hence, propelling the growth over the forecast period.

Key players are adopting strategic initiatives such as product launches, partnerships, and expansion strategies to increase their market share across the globe. For instance, in June 2022, BIOFRONTERA AG announced that its license and marketing authorization holder Louis Widmer SA based in Switzerland has received an extension of its marketing authorization for the management of actinic keratosis in the trunk, extremities, and neck with Ameluz. Moreover, in July 2020, BIOFRONTERA AG announced that it has signed an agreement with Galenica AB for the marketing of BF-RhodoLED and Ameluz in Norway, Finland, Norway, and Iceland.

Actinic Keratosis Treatment Market Report Highlights

• In 2021, the surgery segment dominated the market owing to the rising adoption of cryotherapy surgery in the management of actinic keratosis

• The nucleoside metabolic inhibitor segment held the largest share in 2021 and is expected to retain its dominance over the forecast period

• Asia Pacific is expected to register the highest CAGR over the forecast period due to factors such as the high prevalence of AK, rapidly evolving healthcare infrastructure, and rising healthcare expenditures by Asia Pacific countries

• North America dominated in 2021 due to the rising awareness among people about actinic keratosis, availability of robust treatment options, and improvements in healthcare infrastructure

❖ レポートの目次 ❖

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’S Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details OF Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity flow approach
1.6.1.2 Approach 2: Country wise Market estimation using bottom up approach
1.6.1.3 Approach 3: Country wise Market estimation using top down approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 Key KoL Responses
1.10 Market Share Calculations
1.11 List of Secondary Sources
1.12 Objectives
1.12.1 Objective 1
1.12.2 Objective 2
1.13 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Actinic Keratosis Treatment Market – Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Lineage Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 Increasing prevalence of actinic keratosis coupled with rising geriatric population
3.3.1.2 Rising awareness among people and presence of robust treatment options
3.3.2 Market Restraints Analysis
3.3.2.1 Availability of generic preparations
3.3.2.2 Side effects associated with the drug treatment
3.4 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.5 Industry Analysis – Porter’s
3.6 Reimbursement & Regulatory Scenario
3.7 Major Deals & Strategic Alliances
3.7.1 NEW Product Launch
3.7.2 Acquisition
3.7.3 Expansion
3.7.4 Partnership
3.7.5 Marketing & Promotions
3.7.5.1 Market entry strategies
3.7.9 Consumer Behavior Analysis
Chapter 4 Actinic Keratosis Treatment Market Analysis: Therapy Scope, 2018 – 2030 (Revenue, USD Million)
4.1 Actinic Keratosis Treatment Market: Therapy Movement Analysis
4.2 Surgery
4.2.1 Surgery Market Estimates And Forecast, 2018 – 2030 (USD Million)
4.3 Topical
4.3.1 Topical Market Estimates And Forecast, 2018 – 2030 (USD Million)
4.4 Photodynamic Therapy
4.4.1 Photodynamic Therapy Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 5 Actinic Keratosis Treatment Market Analysis: Drug Class Scope, 2018 – 2030 (Revenue, USD Million)
5.1 Actinic Keratosis Treatment Market: Drug Class Movement Analysis
5.2 Nucleoside Metabolic Inhibitor
5.2.1 Nucleoside Metabolic Inhibitor Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.3 NSAIDs
5.3.1 NSAIDS Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.4 Immune Response Modifiers
5.4.1 Immune Response Modifiers Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.5 Photoenhancers
5.5.1 Photoenhancers Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.6 Photoenhancers
5.6.1 Photoenhancers Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 6 Actinic Keratosis Treatment Market Analysis: End-use Scope, 2018 – 2030 (Revenue, USD Million)
6.1 Actinic Keratosis Treatment Market: End-use Movement Analysis
6.2 Hospitals
6.2.1 Hospitals Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.3 Private Clinics
6.3.1 Private Clinics Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.4 Homecare
6.4.1 Homecare Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.5 Others
6.5.1 Others Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 7 Actinic Keratosis Treatment Market Analysis, Regional Scope, 2018 – 2030, (Revenue, USD Million)
7.1 Market Share Analysis by Region, 2021 & 2030
7.1.1 North America
7.1.1.1 North America Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.1.1.2 U.S.
7.1.1.2.1 U.S. Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.1.1.3 Canada
7.1.1.3.1 Canada Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.1.2 Europe
7.1.2.1 Europe Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.1.2.2 U.K.
7.1.2.2.1 U.K. Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.1.2.3 Germany
7.1.2.3.1 Germany Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.1.2.4 France
7.1.2.4.1 France Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.1.2.5 Italy
7.1.2.5.1 Italy Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.1.2.6 Spain
7.1.2.6.1 Spain Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.1.3 Asia-Pacific
7.1.3.1 Asia-Pacific Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.1.3.2 Japan
7.1.3.2.1 Japan Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.1.3.3 China
7.1.3.3.1 China Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.1.3.4 India
7.1.3.4.1 India Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.1.3.5 South Korea
7.1.3.5.1 South Korea Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.1.3.6 Australia
7.1.3.6.1 Australia Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.1.4 Latin America
7.1.4.1 Latin America Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.1.4.2 Brazil
7.1.4.2.1 Brazil Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.1.4.3 Mexico
7.1.4.3.1 Mexico Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.1.4.4 Argentina
7.1.4.4.1 Argentina Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.1.5 Middle East And Africa
7.1.5.1 Middle East & Africa Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.1.5.2 South Africa
7.1.5.2.1 South Africa Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.1.5.3 Saudi Arabia
7.1.5.3.1 Saudi Arabia Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.1.5.4 UAE
7.1.5.4.1 UAE Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 8 Actinic Keratosis Treatment Market: Competitive Analysis
8.1 Recent Developments and Impact Analysis, by Key Market Participants
8.1.1 Ansoff Matrix
8.2 Company Categorization
8.2.1 Innovators
8.2.1.1 Market Differentiators
8.3 Vendor Landscape
8.3.1 List Of Key Distributors And Channel Partners
8.3.2 Key Customers
8.3.3 Key Company Market Share Analysis, 2021
8.4 Public Companies
8.4.1 Competitive Dashboard Analysis
8.5 Private Companies
8.5.1 List Of Key Emerging Companies
8.6 Regional Network Map
8.7 Key Regional/Local Competitors for actinic keratosis treatment in Japan, Australia, Korea, India, Singapore, and Europe
8.8 Company Profiles
8.8.1 ALMIRALL S.A.
8.8.1.1 Company overview
8.8.1.2 Financial performance
8.8.1.3 Product benchmarking
8.8.1.4 Strategic initiatives
8.8.2 LEO PHARMA A/S
8.8.2.1 Company overview
8.8.2.2 Financial performance
8.8.2.3 Product benchmarking
8.8.2.4 Strategic initiatives
8.8.3 SUN PHARMACEUTICAL INDUSTRIES LTD.
8.8.3.1 Company overview
8.8.3.2 Financial performance
8.8.3.3 Product benchmarking
8.8.3.4 Strategic initiatives
8.8.4 NOVARTIS AG
8.8.4.1 Company overview
8.8.4.2 Financial performance
8.8.4.3 Product benchmarking
8.8.4.4 Strategic initiatives
8.8.5 GALDERMA
8.8.5.1 Company overview
8.8.5.2 Affymetrix
8.8.5.3 Company overview
8.8.5.4 Financial performance
8.8.5.5 Product benchmarking
8.8.5.6 Strategic initiatives
8.8.6 ORTHO DERMATOLOGICS (BAUSCH HEALTH COMPANIES INC.)
8.8.6.1 Company overview
8.8.6.2 Financial performance
8.8.6.3 Product benchmarking
8.8.6.4 Strategic initiatives
8.8.7 BIOFRONTERA AG
8.8.7.1 Company overview
8.8.7.2 Financial performance
8.8.7.3 Product benchmarking
8.8.7.4 Strategic initiatives
8.8.8 HILL PHARMACEUTICALS, INC.
8.8.8.1 Company overview
8.8.8.2 Financial performance
8.8.8.3 Product benchmarking
8.8.8.4 Strategic initiatives



★調査レポート[世界の日光角化症治療市場2022-2030:治療別(局所、手術、光線力学療法)、薬剤分類別、最終用途別、地域別] (コード:GRV22NV006)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の日光角化症治療市場2022-2030:治療別(局所、手術、光線力学療法)、薬剤分類別、最終用途別、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆